Cloverleaf Bio raises $33M seed to build RNA-based cancer drugs
What's the deal? Cloverleaf BioDealroom has a profile for this one. Try Dealroom →, a New Haven-based RNA therapeutics company, has closed a $33 million seed round led by 4BIO CapitalDealroom has a profile for this one. Try Dealroom →. Strategic investors AbbVie Ventures, Eli Lilly and CompanyDealroom has a profile for this one. Try Dealroom →, and Boehringer Ingelheim Venture FundDealroom has a profile for this one. Try Dealroom → also joined, alongside Draper Associates, Mission BioCapitalDealroom has a profile for this one. Try Dealroom →, and American Cancer SocietyDealroom has a profile for this one. Try Dealroom → BrightEdge.
What's the endgame? The Yale spinout is developing a novel class of engineered transfer RNA (tRNA) payloads for cancer. Its platform works by inhibiting RNA-modifying enzymes that cancer cells rely on to proliferate.
Where does the money go? The proceeds will advance two lead programs: an inhibitory tRNA asset targeting hepatocellular carcinoma through early clinical testing, and an antibody-tRNA conjugate targeting colorectal cancer through preclinical development.
Why it matters: Three major pharmaceutical venture arms backing a company at the preclinical stage is unusual. Chief executive officer Austin Draycott said the strategic interest "reflects the level of scientific interest in this approach," adding that the company looks forward to "delivering the data that will test that conviction."
Draycott also credited early funding from the National Cancer Institute's small business research programs. "Federally funded research was foundational to getting this platform off the ground," he said.
What the backers say: Dima Kuzmin, co-founder and managing partner at 4BIO Capital, said Cloverleaf built its platform "from a first-principles insight into a mechanism that the field has largely taken for granted for sixty years." He called the preclinical data on potency and selectivity "compelling."
The signal: At $33 million, Cloverleaf's seed sits in roughly the top 1% of US health seed rounds on record. The scale of the round — and the lineup of corporate backers arriving before human trials — points to how aggressively pharma is chasing early positions in next-generation RNA therapeutics.
Read more: pr.hattiesburg.com
Image credit: National Institutes of Health (NIH)
